News

2nd International Meeting on CardiOncology

Admin • CCON • 5/3/2017

2nd International Meeting on CardiOncology June 15-16, 2017 Dan Panorama Hotel, Tel-Aviv, Israel The field of cancer care has evolved over the past 20 years with the development of more... Read more »

1st Cardio-Oncology Symposium in Mexico

Admin • CCON • 5/3/2017

1st Cardio-Oncology Symposium in Mexico  May 24-27, 2017  Auditorio del Instituto Nacional de Ciencias Medicas y Nutricion “Salvador Zubiran” Mexico, CDMX, Mexico   Program Register Here 

2017 MSK Cardio-Oncology Symposium

Admin • CCON • 5/3/2017

2017 MSK Cardio-Oncology Symposium: Cardiovascular Health and Disease During and After Cancer Therapy – A Case Based Curriculum   Date & Location Friday, May 12, 2017 7:00 AM – Saturday,... Read more »

Cardio-Oncology in China – A New Frontier!

Admin • CCON • 12/15/2016

From the first Cardio-Oncology workshop in June 2016 to a national meeting in November, the First Affiliated Hospital of Dalian Medical University in partnership with Peony Solutions, accelerates growth of... Read more »

Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy

Admin • CCON • 7/31/2016

Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy Canadian Journal of Cardiology, July 2016, Volume 32, Issue 7, Pages 831–841 Read Article Here

Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the Matter

Admin • CCON • 2/2/2016

Chau T. Dang, Anthony F. Yu, Lee W. Jones, Jennifer Liu, Richard M. Steingart, Daniel F. Argolo, Larry Norton and Clifford A. Hudis Journal of Clinical Oncology Published online before print. February 1, 2016, doi:10.1200/JCO.2015.64.5515JCO February 1, 2016 JCO645515 Read Article

Cardiac Meds Appear to Protect Heart From Herceptin Damage

Admin • CCON • 12/15/2015

SAN ANTONIO ― Breast cancer patients treated with trastuzumab (Herceptin, Genentech, Inc) had significantly lower risk for left ventricular (LV) dysfunction and consequent treatment interruptions when treated prophylactically with heart... Read more »

KU hospital program promotes heart health for cancer patients

Admin • CCON • 12/14/2015

KANSAS CITY, Kan. —A program at the University of Kansas Hospital is now combining cardiology and oncology. Read More

Mixed Results for Herceptin Cardiotoxicity Prevention

Admin • CCON • 12/10/2015

Neither a beta-blocker nor an angiotensin-converting enzyme (ACE) inhibitor, used as prophylaxis against trastuzumab’s (Herceptin) adverse cardiac effects, successfully prevented left ventricle remodelling in breast cancer patients in a randomized... Read more »

Prophylactic Heart Failure Pharmacotherapy Is Safe and Effective in Patients With HER2-overexpressing Breast Cancer

Admin • CCON • 12/9/2015

SAN ANTONIO, TX—Results from the MANTICORE trial include prophylactic use of standard heart failure (HF) pharmacotherapy prevents trastuzumab-associated left ventricular ejection fraction (LVEF) and reduces treatment interruptions due to left... Read more »